Just read the news about the use of Rituximab in RA patients. looks like encouraging trial for the early use of rituximab.
Hope for millions as drug stops arthritis in its tracks | Mail Online
I am very concerned about the safety/effectivity of this drug as mom has been diagonised with RA (by one dr, 2 other drs rejected the diagnosis and said it is still early to conclude). she's started on methotrexate 15mg ONCE weekly, meloxicam, folic acid to prevent anemia and sulfasalazine. sadly, i believe its RAeven tho RF value was not high (while ESR value was somehow high) and all the symptoms present.
My question is, does anyone has any doubt that NICE might have rejected the use of some drugs on early stages (anti-TNF alpha, rituximab) based on economical reasons (anti-TNF alpha prescribed for one patient cost the same as treating 10 patients with Methorexate/sulfasalazine).
Last month, a rheumatologist back home said metho+sulfa are enough and historically proven to be safe, so he does not think rituximab is needed for now.
Now, what happens next? more trials to support this claim, then NICE might consider changing the guidance?
at uni, was told that NICE make the decision based on effectivity of drugs, not the monetary cost, then PCT needs to find a way to secure the funding if NICE changed the guidance.
In reality, i am not sure how honest they make these decisions. would make a big difference for my mom as back home there is no NHS and people pay for their treatments (unless they have some kind of insurance). anyone suspecting that NICE playing this game based on financial costs (more than potency/effectivity), as obviously PCTs can't secure funding to shift 500 000 RA patient from metho to rituximab (expensive drug).
I will look into how NICE works soon, any NICE specialist around?


even tho RF value was not high (while ESR value was somehow high) and all the symptoms present.
Reply With Quote
